Oslo, Norway, February 5, 2021 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of novel
vaccine and immunotherapies, announced today that its CFO, Lars Dencker Nielsen,
is stepping down and will leave the Company at the end of the month.

Vaccibody has retained a leading global executive search company to lead the
search for a new CFO who will command the relevant competences and international
experience to support the Company's continued international growth and capital
market strategy, including a possible international listing of the Company's
shares. The recruitment process is expected to be concluded within six months.

To ensure a diligent and safe handling of Vaccibody's financial and IT functions
until a new CFO has been recruited, Vaccibody has contracted with EY for a
qualified interim CFO.


About Vaccibody 
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer